Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis

Wu,Li-Sheng; Wang,Hong; Geng,Xiao-Ping

doi:10.3892/etm.2011.385

Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis

Authors:
- Li-Sheng Wu
- Hong Wang
- Xiao-Ping Geng
View Affiliations

Affiliations: Department of General Surgery, The Third Affiliated Hospital of Anhui Medical University, Hefei 230061, P.R. China, Department of General Surgery, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, P.R. China
Published online on: November 21, 2011 https://doi.org/10.3892/etm.2011.385
Pages: 200-206

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this present meta-analysis is to provide an accurate estimation of the association between two IL28B polymorphisms (rs8099917 and rs12979860) and sustained virological response (SVR) to standard treatment of patients of different racial descent infected with different genotypes of hepatitis C virus (HCV), and also to investigate the possible factors in the IL28B gene that contribute to the different SVR rates of patients with different subtypes of HCV infection across different populations. The electronic database PubMed was searched. Asian patients with a common homozygote (TT vs. TG/GG, OR=3.17; CC vs. CT/TT, OR=3.75) attained a higher rate of SVR, and a similar result was observed in European patients (TT vs. TG/GG, OR=1.74; CC vs. CT/TT, OR=2.50). Furthermore, HCV1-infected patients with a common homozygote (TT vs. TG/GG, OR=2.95; CC vs. CT/TT, OR=4.34) appeared to have a higher SVR rate than those with HCV2/3 (TT vs. TG/GG, OR=1.56; CC vs. CT/TT, OR=1.37). The frequency of the common homozygote in Asian patients was high, followed by European patients and African patients. In all, Asian patients attained a higher SVR rate than European patients (P<0.05). Patients with HCV1 infection had a lower SVR rate than those with HCV2/3 infection (P<0.001). Our results suggest that both the common allele frequency and racial descent itself contribute to the difference in SVR rates across different population groups, and the common allele frequency may partly elucidate the different SVR rates in patients with different genotypes of HCV.

View Figures

View References

1.	GM LauerBD WalkerHepatitis C virus infectionN Engl J Med3454152200110.1056/NEJM20010705345010711439948
2.	DL ThomasLB SeeffNatural history of hepatitis CClin Liver Dis9383398200510.1016/j.cld.2005.05.00316023972
3.	JG McHutchisonEJ LawitzML ShiffmanPeginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionN Engl J Med361580593200910.1056/NEJMoa080801019625712
4.	AJ ThompsonAJ MuirMS SulkowskiInterleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusGastroenterology139120129.e18201010.1053/j.gastro.2010.04.013
5.	CL ThioDL ThomasM CarringtonChronic viral hepatitis and the human genomeHepatology31819827200010.1053/he.2000.431610733534
6.	AJ MuirJD BornsteinPG KillenbergPeginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whitesN Engl J Med35022652271200410.1056/NEJMoa03250215163776
7.	HS ConjeevaramMW FriedLJ JeffersPeginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1Gastroenterology131470477200610.1053/j.gastro.2006.06.00816890601
8.	MW FriedML ShiffmanKR ReddyPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med347975982200210.1056/NEJMoa02004712324553
9.	MP MannsJG McHutchisonSC GordonPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet358958965200110.1016/S0140-6736(01)06102-511583749
10.	M LaggingG AskariehF NegroResponse prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphismsPLoS One6e17232201110.1371/journal.pone.001723221390311
11.	DL ThomasCL ThioMP MartinGenetic variation in IL28B and spontaneous clearance of hepatitis C virusNature461798801200910.1038/nature0846319759533
12.	D GeJ FellayAJ ThompsonGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature461399401200910.1038/nature0830919684573
13.	V SuppiahM MoldovanG AhlenstielIL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyNat Genet4111001104200910.1038/ng.44719749758
14.	Y TanakaN NishidaM SugiyamaGenome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CNat Genet4111051109200910.1038/ng.44919749757
15.	X LiuZ WangJ YuG LeiS WangThree polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysisBreast Cancer Res Treat124821825201010.1007/s10549-010-0910-320437198
16.	WB ZhouDQ XueXA LiuQ DingS WangThe influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysisJ Cancer Res Clin Oncol13710531060201110.1007/s00432-011-0979-z21499874
17.	J NattermannM VogelHD NischalkeGenetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis CJ Infect Dis203595601201110.1093/infdis/jiq09821257738
18.	J LauJP IoannidisCH SchmidQuantitative synthesis in systematic reviewsAnn Intern Med127820826199710.7326/0003-4819-127-9-199711010-000089382404
19.	R DerSimonianN LairdMeta-analysis in clinical trialsControl Clin Trials7177188198610.1016/0197-2456(86)90046-23802833
20.	N MantelW HaenszelStatistical aspects of the analysis of data from retrospective studies of diseaseJ Natl Cancer Inst22719748195913655060
21.	CN HayesM KobayashiN AkutaHCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapyGut60261267201110.1136/gut.2010.22349521068134
22.	A RauchZ KutalikP DescombesGenetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyGastroenterology1381338134545 e17201010.1053/j.gastro.2009.12.05620060832
23.	E AparicioM PareraS FrancoN Perez-AlvarezC TuralB ClotetMA MartinezIL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patientsPLoS One5e13771201010.1371/journal.pone.001377121048934
24.	J GrebelyK PetoumenosM HellardPotential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infectionHepatology5212161224201010.1002/hep.2385020803561
25.	ML YuCF HuangJF HuangRole of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patientsHepatology53713201110.1002/hep.2397621254157
26.	CS HsuSJ HsuHC ChenAssociation of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapyProc Natl Acad Sci USA10837193724201110.1073/pnas.110034910821321200
27.	A MoghaddamE MelumN ReintonH Ring-LarsenH VerbaanK BjøroO DalgardIL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infectionHepatology53746754201110.1002/hep.2415421374656
28.	JY ChenCY LinCM WangIL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infectionGenes Immun12300309201110.1038/gene.2011.121346780
29.	TM ScherzerH HoferAF StaettermayerEarly virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirinJ Hepatol54866871201110.1016/j.jhep.2010.08.02421145807
30.	N SakamotoM NakagawaY TanakaAssociation of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2bJ Med Virol83871878201110.1002/jmv.22038
31.	M KurosakiY TanakaN NishidaPre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factorsJ Hepatol54439448201110.1016/j.jhep.2010.07.037
32.	T KawaokaCN HayesW OhishiPredictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2bJ Hepatol54408414201110.1016/j.jhep.2010.07.03221112660
33.	PY BochudS BibertF NegroIL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis CJ HepatolFeb2011(E-pub ahead of print).
34.	C SarrazinS SusserA DoehringImportance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patientsJ Hepatol54415421201110.1016/j.jhep.2010.07.04121112657
35.	A MangiaAJ ThompsonR SantoroAn IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic responseGastroenterology1398218277 e1201010.1053/j.gastro.2010.05.07920621700
36.	JJ McCarthyJH LiA ThompsonReplicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirinGastroenterology13823072314201010.1053/j.gastro.2010.02.00920176026
37.	JA PinedaA CaruzA RiveroPrediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virusClin Infect Dis51788795201010.1086/65623520804372
38.	MA Montes-CanoJR Garcia-LozanoC Abad-MolinaInterleukin-28B genetic variants and hepatitis virus infection by different viral genotypesHepatology523337201010.1002/hep.2362420578254
39.	M HondaA SakaiT YamashitaHepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis CGastroenterology139499509201010.1053/j.gastro.2010.04.04920434452
40.	ES De AraujoH DahariSJ CotlerTJ LaydenAU NeumannCE MeloAA BaronePharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patientsJ Acquir Immune Defic Syndr5695992011
41.	JM DarlingJ AerssensG FanningQuantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseHepatology531422201110.1002/hep.2405621254158
42.	T ReibergerK RutterA FerlitschPortal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with HCV infectionClin Gastroenterol Hepatol9602608201110.1016/j.cgh.2011.03.00221397726
43.	L YangY LuoJ WeiS HeIntegrative genomic analyses on IL28RA, the common receptor of interferon-λ1, -λ2 and -λ3Int J Mol Med25807812201020372826
44.	L YangJ WeiS HeIntegrative genomic analyses on interferon-λs and their roles in cancer predictionInt J Mol Med252993042010
45.	KK YanM GuirgisT DinhJ GeorgeA DevA LeeA ZekryTreatment responses in Asians and Caucasians with chronic hepatitis C infectionWorld J Gastroenterol1434163420200810.3748/wjg.14.341618528940
46.	CH LiuCJ LiuCL LinPegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trialClin Infect Dis4712601269200810.1086/592579